MCL1 and lymphoma: As most of the lymphoma cells showed sensitivity to either, or in many cases both, BCL-2 and MCL-1 inhibitors, this raises the possibility that combinations of BH3-mimetics targeting MCL-1 and BCL-2, perhaps with addition of further anti-cancer agents, could have a place in the treatment of patients with DHL.